Name: LY3002813
Synonyms: N3pG-Aβ Monoclonal Antibody
Therapy Type: Immunotherapy (passive) (timeline)
Target Type: Amyloid-Related (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Phase 1)
Company: Eli Lilly & Co.


LY3002813 is a monoclonal antibody developed from mouse mE8-IgG2a. This antibody recognizes Aβ(p3-42), a pyroglutamate form of Aβ that is aggregated in amyloid plaques. Most Aβ antibodies in therapeutic development bind various soluble or insoluble species but have low affinity to deposited amyloid plaques. The rationale behind LY3002813 is that targeting deposited plaque itself is necessary to clear existing amyloid burden from the brain, rather than merely prevent deposition of new plaques or growth of existing plaques. Some previous plaque-binding antibodies have been abandoned because they caused microhemorrhages in the brain. The mE8 antibody was reported to clear plaques in mice without causing microhemorrhages (deMattos et al., 2012). 

At the 2014 AAIC conference, Lilly reported that a randomized preclinical study of combination therapy with LY3002813 and the BACE inhibitor LY2811376 cleared more than 80 percent of amyloid from the brains of PDAPP-transgenic mice, compared to about 50 percent clearance each for the respective monotherapies. Neuropathology studies showed that LY3002813 removed both cored and diffuse plaques (see Jul 2014 conference news).


In May 2013, Lilly started a Phase 1 study in 100 people with mild cognitive impairment due to Alzheimer's disease, or mild Alzheimer's disease, in the United States and Japan. Participants had to have a positive amyloid PET scan. This seven-arm study evaluates five intravenous doses, from 0.1 mg/kg to 10 mg/kg, infused monthly up to four times, and a single subcutaneous injection against placebo for safety, pharmacokinetics, and pharmacodynamics. It was originally listed to run until 2015 but has been extended to January 2017. At the 2016 AAIC conference in Toronto, Lilly scientists presented results from 49 patients, average age 74, who had completed the trial. Thirty-seven volunteers received a single initial dose, 12 placebo. After adverse event monitoring, they received up to four additional monthly infusions of the same dose; people in the 0.1mg/kg cohort subsequently received 0.3mg/kg. The highest dose was reported to reduce plaque load in the brain, though that group had but six participants. Overall, their mean florbetapir SUVR fell from 1.65 at baseline by 0.26 over seven months, corresponding to a 40 percent reduction. No cases of ARIA were seen in this small trial, but there were two asymptomatic cases of ARIA-H. The antibody was reported to be strongly immunogenic. In the multiple-dose phase, six of the 37 patients had an infusion reaction with chills, flushing, dizziness, rash, and fever, and anti-drug antibodies in plasma (see Aug 2016 conference news).

In December 2015, Lilly started a second Phase 1 study in 150 people with the same diagnosis, again in the United States and Japan. This trial also starts with a single dose and safety monitoring, but it then proceeds to repeated dosing for up to 18 months. The study measures primarily LY3002813's effect on brain amyloid load with florbetapir PET; secondary outcomes include blood pharmacokinetics of LY3002813 and auto-antibodies directed against this biologic drug. The trial is expected to run until 2019.

For all trials of this antibody, see


No Available Comments

Make a Comment

To make a comment you must login or register.


News Citations

  1. New Ways to Target Aβ and BACE Show Promising Phase 1 Data
  2. Anti-Amyloid Therapies Combine Forces to Knock Out Plaques

Paper Citations

  1. . A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice. Neuron. 2012 Dec 6;76(5):908-20. PubMed.

External Citations


Further Reading